References
Hainsworth J, Litchy S, Burris H 3rd et al (2003) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol 20:4261–4267
Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22(23):4711–4716
Marcus R, Imrie K, Belch A et al (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105(4):1417–1423
Martinelli G, Laszlo D, Bertolini F et al (2003) Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin’s lymphoma. Br J Haematol 123(2):271–277
Kaplan LD, Lee JY, Ambinder RF et al (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-malignancies consortium trial 010. Blood 106:1538–1543
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Laszlo, D., Bassi, S., Andreola, G. et al. Peripheral T-lymphocyte subsets in patients treated with Rituximab–Chlorambucil combination therapy for indolent NHL. Ann Hematol 85, 813–814 (2006). https://doi.org/10.1007/s00277-006-0170-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-006-0170-9